Drug is indicated for use in patients with disease that has progressed on prior combination chemotherapy or in patients who are intolerant to such therapy. 1 h. Therapy may continue for as long as patient does not progress, shows no evidence of cardiotoxicity, and continues to tolerate treatment. At least 4 courses are recommended. If following following guideliens, do not increase reduced doses at a later time. If test results indicate possible cardiac injury, weigh expected benefit against potential risks.
Leukopenia is usually transient with use of recommended dosage.
Development of sepsis related to neutropenia has resulted in discontinuation and, rarely, death. Advise women of childbearing potential to avoid pregnancy. Contraindicated in patients with a history of hypersensitivity to a conventional formulation of doxorubicin hydrochloride or to any component. Use in patients with a history of cardiovascular disease only when potential benefit outweighs potential risk. Long-term cardiac effects in patients relative to conventional doxorubicin not adequately evaluated.